I期临床-话题@MedSci

#I期临床#

570篇内容 | 7001人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652750, encodeId=89ca1652e50f5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Diabetes Care：人类胰岛移植完成III期临床根治1型糖尿病已见曙光！, objectType=article, longId=67059, objectId=ec036e059b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec036e059b8, replyNumber=0, likeNumber=69, createdTime=2017-03-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec036e059b8, moduleTitle=Diabetes Care：人类胰岛移植完成III期临床根治1型糖尿病已见曙光！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec036e059b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652761, encodeId=13dc1652e617a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, objectType=article, longId=71847, objectId=9b2ae184708, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b2ae184708, replyNumber=0, likeNumber=64, createdTime=2017-05-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b2ae184708, moduleTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b2ae184708)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652763, encodeId=29201652e6389, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Sutent（舒坦）辅助治疗肾细胞癌III期临床获得成功（S-TRAC研究）, objectType=article, longId=72833, objectId=6650e283369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6650e283369, replyNumber=0, likeNumber=87, createdTime=2016-11-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6650e283369, moduleTitle=Sutent（舒坦）辅助治疗肾细胞癌III期临床获得成功（S-TRAC研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6650e283369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652765, encodeId=81281652e65da, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点, objectType=article, longId=73929, objectId=f3abe392977, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3abe392977, replyNumber=0, likeNumber=64, createdTime=2017-03-11, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3abe392977, moduleTitle=阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3abe392977)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652772, encodeId=87af1652e7274, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, objectType=article, longId=77934, objectId=92cfe7934e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cfe7934e2, replyNumber=0, likeNumber=66, createdTime=2017-07-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cfe7934e2, moduleTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cfe7934e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652762, encodeId=86dd1652e62fa, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功, objectType=article, longId=71850, objectId=e5a0e1850d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a0e1850d9, replyNumber=0, likeNumber=66, createdTime=2017-06-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a0e1850d9, moduleTitle=辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a0e1850d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652751, encodeId=c2ed1652e5191, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功, objectType=article, longId=67827, objectId=d4666e827af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4666e827af, replyNumber=0, likeNumber=71, createdTime=2016-06-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4666e827af, moduleTitle=消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4666e827af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652749, encodeId=5d7e1652e491a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功, objectType=article, longId=66979, objectId=0c7b669e992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7b669e992, replyNumber=0, likeNumber=69, createdTime=2016-09-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7b669e992, moduleTitle=乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c7b669e992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652760, encodeId=6f661652e608b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=武田全球诺罗病毒（norovirus）疫苗TAK-214进入II期临床开发, objectType=article, longId=71371, objectId=00a9e137141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a9e137141, replyNumber=0, likeNumber=73, createdTime=2016-08-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a9e137141, moduleTitle=武田全球诺罗病毒（norovirus）疫苗TAK-214进入II期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a9e137141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652759, encodeId=11021652e5960, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, objectType=article, longId=71290, objectId=e56ee129027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56ee129027, replyNumber=0, likeNumber=88, createdTime=2016-07-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56ee129027, moduleTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56ee129027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652779, encodeId=9e0f1652e79b8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功, objectType=article, longId=85803, objectId=b71585803c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b71585803c3, replyNumber=0, likeNumber=66, createdTime=2017-10-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b71585803c3, moduleTitle=罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b71585803c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652754, encodeId=f1791652e54fd, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, objectType=article, longId=70373, objectId=0c80e0373e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c80e0373e2, replyNumber=0, likeNumber=73, createdTime=2017-03-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c80e0373e2, moduleTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c80e0373e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652743, encodeId=82071652e43d8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, objectType=article, longId=63534, objectId=bde06353427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde06353427, replyNumber=0, likeNumber=65, createdTime=2016-11-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde06353427, moduleTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde06353427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652744, encodeId=fb7b1652e44d5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功, objectType=article, longId=63843, objectId=fe1b6384351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe1b6384351, replyNumber=0, likeNumber=90, createdTime=2016-03-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe1b6384351, moduleTitle=超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe1b6384351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652746, encodeId=6df01652e46ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报, objectType=article, longId=65458, objectId=5736654581e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5736654581e, replyNumber=0, likeNumber=64, createdTime=2016-10-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5736654581e, moduleTitle=苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5736654581e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652773, encodeId=ef0d1652e7320, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, objectType=article, longId=78308, objectId=7164e8308d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7164e8308d1, replyNumber=0, likeNumber=106, createdTime=2017-05-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7164e8308d1, moduleTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7164e8308d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652747, encodeId=8d4b1652e4708, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, objectType=article, longId=65585, objectId=4f7365585cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f7365585cc, replyNumber=0, likeNumber=65, createdTime=2016-09-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f7365585cc, moduleTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f7365585cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652768, encodeId=e8821652e6850, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功, objectType=article, longId=75977, objectId=1959e5977e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1959e5977e7, replyNumber=0, likeNumber=64, createdTime=2017-07-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1959e5977e7, moduleTitle=诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1959e5977e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652774, encodeId=4a601652e7458, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=老年性痴呆药物再失败！灵北5-HT6受体拮抗剂idalopirdineIII期临床未改善轻度至中度AD患者认知, objectType=article, longId=78706, objectId=3481e870661, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3481e870661, replyNumber=0, likeNumber=64, createdTime=2017-03-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3481e870661, moduleTitle=老年性痴呆药物再失败！灵北5-HT6受体拮抗剂idalopirdineIII期临床未改善轻度至中度AD患者认知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3481e870661)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652764, encodeId=55781652e6478, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, objectType=article, longId=73839, objectId=0b9ee38391d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9ee38391d, replyNumber=0, likeNumber=63, createdTime=2017-01-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9ee38391d, moduleTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9ee38391d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Diabetes Care：人类胰岛移植完成III期临床根治1型糖尿病已见曙光！

2017-03-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功

2017-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Sutent（舒坦）辅助治疗肾细胞癌III期临床获得成功（S-TRAC研究）

2016-11-09

柳叶一刀 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点

2017-03-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功

2017-07-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功

2017-06-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功

2016-06-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功

2016-09-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

武田全球诺罗病毒（norovirus）疫苗TAK-214进入II期临床开发

2016-08-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点

2016-07-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功

2017-10-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）

2017-03-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功

2016-11-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功

2016-03-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报

2016-10-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压

2017-05-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点

2016-09-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功

2017-07-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

老年性痴呆药物再失败！灵北5-HT6受体拮抗剂idalopirdineIII期临床未改善轻度至中度AD患者认知

2017-03-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据

2017-01-03

科室
- - 订阅+
  - 更多科室
工具
服务